Verastem posts $11.2M Q3 product revenue, GAAP net loss $98.5M

Verastem, Inc.

2025-Q3 EPS reported -$2.73 revenue$13,379,000

AVMAPKI FAKZYNJA CO-PACK achieved $11.2 million net product revenue in first full quarter of launch.
GAAP net loss $98.5M ($1.35/share) vs $24.0M ($0.60) YoY; non-GAAP adjusted net loss $39.4M ($0.54/share).
Cash $137.7M; with product revenue and warrant exercises, runway into H2 2026.
VS-7375 cleared 400 mg and 600 mg QD monotherapy with no DLTs; no nausea/vomiting/diarrhea >Grade 1.
RAMP 301 (LGSOC) completed targeted enrollment of 270 patients early; IDMC recommended 29 additional patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.